{
    "clinical_study": {
        "@rank": "33565", 
        "arm_group": {
            "arm_group_label": "Nimotuzumab nab-paclitaxel cisplatin", 
            "arm_group_type": "Experimental", 
            "description": "Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).\nCisplatin: 75mg/m2,IV on days 1\uff0c22.\nNab-paclitaxel: 125mg/m2,IV on days 1,8,22,29.\npatients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
        }, 
        "brief_summary": {
            "textblock": "Nimotuzumab, a humanized monoclonal antibody against epidermal growth factor receptor\n      (EGFR),has been shown to be effective and safe in some studies with head-neck\n      cancers.Nab-paclitaxel regimen in advanced NSCLC has a better tumor response rate and safety\n      than solvent-based paclitaxel.However,the safety and efficacy of Nimotuzumab plus\n      nab-paclitaxel regimen is uncertain in neoadjuvant therapy in esophageal cancer.The\n      investigators then initiated a phase II clinical trial with Nimotuzumab plus\n      Nab-paclitaxel/cisplatin as the neoadjuvant chemotherapy in patients with locally advanced\n      esophageal squamous cell carcinoma to observe the efficacy and safety of the combination."
        }, 
        "brief_title": "Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Squamous Cell Carcinoma of Esophagus", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Esophageal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "In the past decade, clinical trials have evaluated the role of neoadjuvant chemotherapy,\n      radiation, or both, for patients with surgically resectable esophageal carcinoma, but have\n      all failed to demonstrate a consistent survival benefit. In Eastern countries, preoperative\n      chemotherapy followed by radical surgery became one of the treatment strategies for\n      resectable, clinical stage II or III esophageal cancer. In an effort to improve the efficacy\n      of systemic chemotherapy, we conducted a prospective study to evaluate the regimen of\n      Nimotuzumab plus Nab-paclitaxel/cisplatin as perioperative therapy for patients with\n      resectable esophageal squamous cell carcinoma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed squamous cell carcinoma of the thoracic esophagus, including\n             the gastroesophageal junction (Siewert type I)\n\n          -  Locally advanced disease that is technically operable with curative intent (R0)\n\n          -  T3, N0 OR T1-3, N+ OR T4, Nx\n\n          -  No T1-2, N0\n\n          -  No inoperable T4 (unequivocal organ involvement)\n\n          -  No distant metastasis, including M1a lymph node status\n\n          -  Lymph nodes suspicious of M1a status by CT scan, PET scan, or ultrasound must be\n             verified by fine-needle aspiration cytology\n\n          -  No carcinoma of the cervical esophagus\n\n          -  Obstructive tumors allowed\n\n        Exclusion Criteria:\n\n          -  Not suitable to surgery\n\n          -  cervical Esophageal Carcinoma(distance of incisor tooth<19cm)\n\n          -  early Esophageal Carcinoma(Stage I)\n\n          -  complete esophageal obstruction\uff0cEsophageal perforation or hematemesis\n\n          -  other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma\n             in situ\n\n          -  pregnant or breast-feeding women or people during the birth-period who refused to\n             take contraceptives\n\n          -  Uncontrolled seizures or psychiatric diseases, loss of control over their own\n             behavior\n\n          -  History of serious allergic or castor oil allergy\n\n          -  Patients who are not suitable to participate in the trial according to researchers"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02041819", 
            "org_study_id": "ZYTOP1405"
        }, 
        "intervention": {
            "arm_group_label": "Nimotuzumab nab-paclitaxel cisplatin", 
            "description": "Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).", 
            "intervention_name": "Nimotuzumab", 
            "intervention_type": "Drug", 
            "other_name": "nimo"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Neoadjuvant chemotherapy", 
            "Nimotuzumab", 
            "Nab-Paclitaxel", 
            "Carcinoma of Esophagus"
        ], 
        "lastchanged_date": "January 17, 2014", 
        "location": {
            "contact": {
                "email": "doczq.2008@gmail.com", 
                "last_name": "Qiong Zhao, MD", 
                "phone": "86-0571-87236802"
            }, 
            "facility": {
                "address": {
                    "city": "Zhejiang", 
                    "country": "China", 
                    "state": "Zhejiang", 
                    "zip": "310003"
                }, 
                "name": "The first affiliated hospital, Zhejiang University"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial of Neoadjuvant Chemotherapy With Nimotuzumab Plus Nanoparticle Albumin-bound Paclitaxel and Cisplatin Followed by Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of Esophagus", 
        "overall_contact": {
            "email": "doczq.2008@gmail.com", 
            "last_name": "Qiong Zhao, MD", 
            "phone": "0571-87236802"
        }, 
        "overall_official": {
            "affiliation": "The first affiliated hospital, Zhejiang University", 
            "last_name": "Qiong Zhao, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "pathological response rate and clinical response rate", 
            "measure": "response rate", 
            "safety_issue": "No", 
            "time_frame": "From date of treatment until the date of progression, assessed up to 2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02041819"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zhejiang University", 
            "investigator_full_name": "Qiong Zhao", 
            "investigator_title": "Chief of Department of Thoracic Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Overall survival was measured from the date of treatment to the date of death, or last follow-up,assessed up to 48 months"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Progression-free survival was measured from the date of treatment to the date of first evidence of relapse or death due to any cause,assessed up to 36 months"
            }, 
            {
                "description": "Adverse events were classified according to U.S. National Cancer Institute common toxicity criteria, version 4.0", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "During the chemotherapy,an expected average of 3 weeks"
            }
        ], 
        "source": "Zhejiang University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}